Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study
Authors:
- Rieko NakataniRNRieko Nakatani
- Tadashi WatabeTWTadashi Watabe
- Atsunori FukuharaAFAtsunori Fukuhara
- Toru TakanoTTToru Takano
- Takashi KamiyaTKTakashi Kamiya
- Hidetaka SasakiHSHidetaka Sasaki
- Hiroyuki KurakamiHKHiroyuki Kurakami
- Yukiko NakataYNYukiko Nakata
- Michio OtsukiMOMichio Otsuki
- Yoh HidakaYHYoh Hidaka
- Iichiro ShimomuraISIichiro Shimomura
- 15 October 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , 1004-1020
Abstract
Objective: Radioactive iodine (RAI) is an established therapy for thyroid cancer (TC). The aim of this study was to evaluate the prognosis and disease characteristics based on initial RAI therapy using image findings. Methods: We reviewed the clinical records of 290 TC patients who received initial therapeutic RAI therapy following total thyroidectomy for ablation and treatment between 2010 and 2021. Patients were classified into 3 groups based on the 131I whole-body scintigraphy (WBS) combined with morphological imaging records: non-DM, RAI-non-avid DM, and RAI-avid DM. Progression-free survival (PFS) and overall survival were assessed in each group. Normalized indices were calculated automatically using dedicated software for each patient on WBS. 131I-avid lesions were defined as areas with uptake exceeding the mean + 2 SDs of the reference regions of interest placed at the head-cervical, thoracic, and abdominal-pelvis regions, Watabe proposed. Results: The 5-year and 7-year survival rates for the non-DM, RAI-non-avid DM, and RAI-avid DM groups were 98% to 95%, 86% to 78%, and 82% to 82%, respectively. Average count of 131I-avid area was identified as a significant prognostic factor for PFS, being independent of age, distant metastatic pattern, histological subtype, and T classification. Retreatment was preferably performed within 2 years after the initial RAI therapy, as this period appears to be critical for efficacy. Additionally, the site of metastases was a strong prognostic determinant. Conclusion: Precise imaging evaluation of the initial RAI therapy may help predict the prognosis during the first 5 years, contributing to more effective comprehensive treatment approaches for long-term management.Keywords
This publication has 25 references indexed in Scilit:
- Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survivalEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- RAI thyroid bed uptake after total thyroidectomy: A novel SPECT‐CT anatomic classification systemThe Laryngoscope, 2015
- Long-Term Prognosis of Differentiated Thyroid Cancer with Lung Metastasis in Korea and Its Prognostic FactorsThyroid®, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Subcellular Distribution of the Sodium Iodide Symporter in Benign and Malignant Thyroid TissuesThyroid®, 2012
- The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant MetastasesThyroid®, 2009
- Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosisCancer, 2007
- Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patientsNature Clinical Practice Endocrinology & Metabolism, 2007
- 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinomaCancer, 1996
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994